Search results for " immune system"

showing 10 items of 893 documents

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).

2022

Abstract Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti‐drug antibodies (ADA). Optimal methods to evaluate the potential effects of ADA on clinical outcomes in oncology are not well established. In this study, we assessed efficacy and safety, based on ADA status, in patients from over 10 clinical trials that evaluated the immune checkpoint inhibitor atezolizumab as a single agent or as combination therapy for several types of advanced cancers. ADA can only be observed post randomization, and imbalances in baseline prognostic factors can confound the interpretation of ADA impact. We applied methodology to account for the confoundin…

Oncologymedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesRandomizationCombination therapyDatabases FactualMEDLINERM1-950Antibodies Monoclonal HumanizedGeneral Biochemistry Genetics and Molecular BiologyArticleAtezolizumabimmune system diseasesInternal medicineNeoplasmsmedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsAdverse effectImmune Checkpoint InhibitorsClinical Trials as Topicbusiness.industryGeneral NeuroscienceImmunogenicityResearchConfoundingnutritional and metabolic diseaseshemic and immune systemsGeneral MedicineArticlesAntibodies Monoclonal Humanized/immunology; Antibodies Monoclonal Humanized/pharmacokinetics; Antibodies Neutralizing/immunology; Antibodies Neutralizing/metabolism; Clinical Trials as Topic; Databases Factual; Humans; Immune Checkpoint Inhibitors/immunology; Immune Checkpoint Inhibitors/pharmacokinetics; Neoplasms/drug therapy; Safety; Treatment OutcomeAntibodies NeutralizingClinical trialenzymes and coenzymes (carbohydrates)Treatment OutcomeTherapeutics. PharmacologyPublic aspects of medicineRA1-1270SafetybusinessClinical and translational science
researchProduct

Resolving lesions in human cutaneous leishmaniasis predominantly harbour chemokine receptor CXCR3-positive T helper 1/T cytotoxic type 1 cells

2009

Summary Background  Cutaneous leishmaniasis (CL) is an epidemic disease affecting millions of individuals worldwide. Treatment options have several side-effects and a vaccine does not exist at present. Objectives  To translate information about protection against CL from mice to man, we studied the local immune response in CL skin biopsies and correlated these findings with clinical information. Methods  The frequency of inflammatory cells was determined in skin biopsies of 20 patients diagnosed with CL using immunohistochemistry. In addition, the nature of the resulting adaptive immune response was assessed by (double) immunostaining against CD4 and chemokine receptors CXCR3 (T helper 1, T…

Pathologymedicine.medical_specialtyChemokinebiologyDermatologyCXCR3Acquired immune systemNatural killer cellInterleukin 21Immune systemmedicine.anatomical_structureImmunologymedicinebiology.proteinCytotoxic T cellCD8British Journal of Dermatology
researchProduct

AB0189 Macrophages polarization in the gut of patients with ankylosing spondylitis

2013

Background Subclinical gut inflammation occurs in patients with Ankylosing Spondylitis (AS) and long term evolution to overt Crohn’s disease (CD) has been described in these patients. Gut mucosal macrophages represent the largest pool of tissue macrophages in the body. Different pathways of macrophage activation have been described in humans. Objectives To study the macrophages polarization occurring in the inflamed gut of AS patients. Methods Twenty two consecutive HLA-B27 + Ankylosing Spondylitis (AS) patients, 15 Crohn’s Disease (CD) patients and 15 normal controls were included in this study. Four AS patients developed an overt CD during the follow-up and were included. Ileal macrophage…

Pathologymedicine.medical_specialtyInnate immune systembusiness.industryCD68CD14ImmunologyAcquired immune systemGeneral Biochemistry Genetics and Molecular BiologyRheumatologyImmunologymedicineImmunology and AllergyMacrophagebusinessCD163IRF5STAT6Annals of the Rheumatic Diseases
researchProduct

Mast cell-derived mediators promote murine neutrophil effector functions

2013

Mast cells are able to trigger life-saving immune responses in murine models for acute inflammation. In such settings, several lines of evidence indicate that the rapid and protective recruitment of neutrophils initiated by the release of mast cell-derived pro-inflammatory mediators is a key element of innate immunity. Herein, we investigate the impact of mast cells on critical parameters of neutrophil effector function. In the presence of activated murine bone marrow-derived mast cells, neutrophils freshly isolated from bone marrow rapidly lose expression of CD62L and up-regulate CD11b, the latter being partly driven by mast cell-derived TNF and GM-CSF. Mast cells also strongly enhance neu…

PhagocytosisImmunologyApoptosisInflammation610 Medicine & healthmast cellsBiology142-005 142-005Neutrophil ActivationlungMiceImmune systemPhagocytosisneutrophilsmedicineAnimalsImmunology and AllergyCells CulturedMice Knockout2403 ImmunologyInnate immune systemTumor Necrosis Factor-alpharodentGranulocyte-Macrophage Colony-Stimulating FactorPneumoniaGeneral MedicineFlow CytometryMast cellMice Mutant StrainsCell biologycell activationMice Inbred C57BLInterleukin 33medicine.anatomical_structureinflammationImmunology2723 Immunology and AllergyTumor necrosis factor alphamedicine.symptomCell activation
researchProduct

Inactivation of an Enveloped Virus by Immobilized Antimicrobial Peptides.

2021

Infections caused by viruses are difficult to treat due to their life cycle, which depends on the replication machinery of the respective host cells. Commonly used antiviral strategies are based upon the application of, e.g., entry inhibitors and other compounds that interfere with virus replication. Besides possible side effects, the rapid occurrence of viral resistance poses a great challenge. Antimicrobial peptides (AMPs), as a component of the innate immunity, are able to kill bacteria and fungi and, in addition, may inactivate enveloped viruses. Many AMPs exert their biological function by impairing microbial and viral membranes. As a result, membrane integrity is lost, leading to bact…

PharmacologyInnate immune systembiologyChemistryOrganic ChemistryAntimicrobial peptidesBiomedical EngineeringPharmaceutical ScienceBioengineeringbiology.organism_classificationmedicine.diseaseHemolysisMembraneViral replicationBiochemistryViral envelopemedicineViral loadBacteriaAntimicrobial PeptidesBiotechnologyBioconjugate chemistry
researchProduct

The effects of the nitric oxide donors molsidomine and SIN-1 on human polymorphonuclear leucocyte functionin vitro andex vivo

1992

The nitrovasodilator and nitric oxide donor molsidomine and its metabolite SIN-I dilate vascular smooth muscle and inhibit platelet activation by increasing intracellular concentrations of cyclic GMP We have therefore studied the effects of molsidomine and SIN-I on isolated human polymorphonuclear leucocytes (PMN)in vitro andex vivo. In vitro molsidomine dose-dependently reducedβ-glucuronidase release and the generation of superoxide anions from non-activated and from FMLP- or PAF-stimulated human PMNs. SIN-1 was equally effective in reducing (β-glucuronidase release and totally inhibited oxygen radical generation at a concentration of 580 μmol · l−1. In a double-blind, placebo-controlled, …

PharmacologyMolsidomineChemistrySuperoxideMetabolitehemic and immune systemsGeneral MedicinePharmacologyNitric oxidechemistry.chemical_compoundBiochemistryIn vivomedicinePharmacology (medical)Platelet activationNitrovasodilatorEx vivomedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study

2021

Background Despite its proven activity as third-line treatment in gastrointestinal stromal tumors (GIST), regorafenib can present a poor tolerability profile which often leads to treatment modifications and transient or permanent discontinuation; thus, in clinical practice physicians usually adopt various dosing and interval schedules to counteract regorafenib-related adverse events and avoid treatment interruption. The aim of this real-world study was to investigate the efficacy and safety of personalized schedules of regorafenib in patients with metastatic GIST, in comparison with the standard schedule (160 mg daily, 3-weeks-on, 1-week-off). Patients and methods Institutional registries a…

Phenylurea CompoundOncologyCancer Researchmedicine.medical_specialtyScheduleStromal cellPyridinesGastrointestinal Stromal TumorsPyridinePersonalized treatmentchemical and pharmacologic phenomenaMultikinase inhibitorchemistry.chemical_compoundQuality of lifeRetrospective Studieimmune system diseaseshemic and lymphatic diseasesInternal medicineRegorafenibmedicineHumansOriginal ResearchRetrospective StudiesGiSTbusiness.industryPhenylurea Compoundstoxicityhemic and immune systemspersonalized treatmentdigestive system diseasesquality of lifeOncologychemistryregorafenibGIST; personalized treatment; quality of life; regorafenib; toxicity; Humans; Phenylurea Compounds; Pyridines; Retrospective Studies; Gastrointestinal Stromal TumorsbusinessHumanGISTESMO Open
researchProduct

Integrin cytoplasmic domain and pITAM compete for spleen tyrosine kinase binding

2019

ABSTRACTIn hematopoietic tissues cell-cell communication involves immunoreceptors and specialized cell adhesion receptors that both mediate intracellular signals. Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase involved in the downstream signaling of both immunoreceptors tyrosine activation motif (ITAM) receptors and integrin family cell adhesion receptors. Both phosphorylated ITAM (pITAM) and integrins bind to the regulatory domain of Syk composed of two Src homology 2 (SH2) domains. The interaction with pITAM is mediated by binding of a specific phosphotyrosine to each of the SH2 domains, leading to conformational changes and Syk kinase activation. Integrins bind to the int…

Phosphotyrosine binding0303 health sciencesbiologyChemistryIntegrinSykchemical and pharmacologic phenomenahemic and immune systemsSH2 domainCell biology03 medical and health sciences0302 clinical medicinebiology.proteinCell adhesionTyrosine kinase030217 neurology & neurosurgery030304 developmental biologyProto-oncogene tyrosine-protein kinase SrcIntegrin binding
researchProduct

Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype

2020

The complement system is an essential component of the innate immune defence that, if overly activated, may damage organs and tissues. For this reason, there is a fine complement regulatory system. The complement modulation system includes two proteins with important regulatory activity, CD55 or decay accelerating factor (DAF) and CD59 or membrane inhibitor of reactive lysis (MIRL). The paroxysmal nocturnal hemoglobinuria (PNH) is a clonal and non-neoplastic disease characterized by intravascular haemolysis, occurrence of thrombosis and bone marrow failure. In clinical practice, in opposition to PNH, a variety of pathological conditions have been observed with an acquired and non-genetic de…

PhysiologyHemoglobinuria ParoxysmalDiseaseCD59030204 cardiovascular system & hematologyHemolysis030218 nuclear medicine & medical imagingSettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesPhysiology (medical)medicineHumansParoxysmal nocturnal hemoglobinuriaDecay-accelerating factorcomplement systemInnate immune systembusiness.industryThrombosisHematologythromboembolic riskmedicine.diseasePhenotypeComplement systemPhenotypemedicine.anatomical_structureImmunologyParoxysmal nocturnal hemoglobinuriaBone marrowCD55Cardiology and Cardiovascular MedicinebusinessCD59
researchProduct

Origin and evolution of arthropod hemocyanins and related proteins.

2002

Arthropod hemocyanins are large, multimeric, (n x 6) copper-containing proteins that deliver oxygen in the haemolymph of many chelicerate, crustacean, myriapod, and also possibly some insect species. The arthropod hemocyanins belong to a large protein superfamily that also includes the arthropod phenoloxidases, certain crustacean and insect storage proteins (pseudo-hemocyanins and hexamerins), and the insect hexamerin receptors. Here I summarise the present knowledge of the origin, functional adaptations, and evolution of these proteins. Arthropod and mollusc hemocyanins are, if at all, only distantly related. As early as in the arthropod stem line, the hemocyanins emerged from a phenoloxid…

Physiologymedia_common.quotation_subjectProtein subunitmedicine.medical_treatmentchemical and pharmacologic phenomenaInsectBiochemistryEvolution MolecularEndocrinologyPhylogeneticsHemolymphmedicineAnimalsArthropodsEcology Evolution Behavior and SystematicsPhylogenymedia_commonbiologyfungihemic and immune systemsHemocyaninAnatomyProtein superfamilybiology.organism_classificationEvolutionary biologyHemocyaninsAnimal Science and ZoologyChelicerataArthropodJournal of comparative physiology. B, Biochemical, systemic, and environmental physiology
researchProduct